# Effect of Sarpogrelate On the Nephropathy in Type 2 Diabetes (SONATA Study)

> **NCT01869881** · PHASE4 · COMPLETED · sponsor: **Yuhan Corporation** · enrollment: 151 (actual)

## Conditions studied

- Diabetic Nephropathy

## Interventions

- **DRUG:** Anplag(Sarpogrelate)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01869881
- **Lead sponsor:** Yuhan Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-02-01
- **Primary completion:** 2014-11-17
- **Final completion:** 2015-01-28
- **Target enrollment:** 151 (ACTUAL)
- **Last updated:** 2021-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01869881

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01869881, "Effect of Sarpogrelate On the Nephropathy in Type 2 Diabetes (SONATA Study)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01869881. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*